Hmdb loader
Survey
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:52 UTC
Update Date2022-03-07 02:52:01 UTC
HMDB IDHMDB0015557
Secondary Accession Numbers
  • HMDB15557
Metabolite Identification
Common NamePheniramine
DescriptionPheniramine is only found in individuals that have used or taken this drug. It is one of the histamine H1 antagonists with little sedative action. It is used in treatment of hay fever, rhinitis, allergic dermatoses, and pruritus. [PubChem]Antihistamines such as pheniramine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. Antihistamines suppress the histamine-induced wheal (swelling) and flare (vasodilation) response by blocking the binding of histamine to its receptors on nerves, vascular smooth muscle, glandular cells, endothelium, and mast cells. They effectively exert competitive antagonism of histamine for H1-receptors.
Structure
Data?1582753310
Synonyms
ValueSource
FeniramineHMDB
PropheniramineHMDB
ProphenpyridamineHMDB
HistapyridamineHMDB
Pheniramine bimaleateHMDB
Aventis brand OF pheniramine maleateHMDB
AvilHMDB
Maleate, pheniramineHMDB
Pheniramine maleateHMDB
Bimaleate, pheniramineHMDB
DaneralHMDB
Chemical FormulaC16H20N2
Average Molecular Weight240.3434
Monoisotopic Molecular Weight240.16264865
IUPAC Namedimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine
Traditional Namepheniramine
CAS Registry Number86-21-5
SMILES
CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1
InChI Identifier
InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
InChI KeyIJHNSHDBIRRJRN-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as pheniramines. Pheniramines are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPheniramines
Direct ParentPheniramines
Alternative Parents
Substituents
  • Pheniramine
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organic nitrogen compound
  • Organopnictogen compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
Process
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point< 25 °CNot Available
Boiling Point175.00 °C. @ 25.00 mm HgThe Good Scents Company Information System
Water Solubility0.38 g/LNot Available
LogP1.110 (est)The Good Scents Company Information System
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+Not Available155.057http://allccs.zhulab.cn/database/detail?ID=AllCCS00000951
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.38 g/LALOGPS
logP2.85ALOGPS
logP2.98ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)9.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 ŲChemAxon
Rotatable Bond Count5ChemAxon
Refractivity76.05 m³·mol⁻¹ChemAxon
Polarizability28.41 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+158.32631661259
DarkChem[M-H]-158.15131661259
DeepCCS[M+H]+152.22430932474
DeepCCS[M-H]-149.86630932474
DeepCCS[M-2H]-182.97230932474
DeepCCS[M+Na]+158.31730932474
AllCCS[M+H]+155.032859911
AllCCS[M+H-H2O]+151.032859911
AllCCS[M+NH4]+158.832859911
AllCCS[M+Na]+159.932859911
AllCCS[M-H]-163.632859911
AllCCS[M+Na-2H]-163.732859911
AllCCS[M+HCOO]-163.932859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
PheniramineCN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N12588.7Standard polar33892256
PheniramineCN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N11843.7Standard non polar33892256
PheniramineCN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N11796.7Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Pheniramine GC-MS (Non-derivatized) - 70eV, Positivesplash10-066r-7910000000-96eb6f4bb716d47647702017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Pheniramine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0920000000-fd728bb396d025cac3f02017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0900000000-7af6ac1b513c7f2f33a92017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0900000000-ea7e67a76460b33d83062017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0900000000-f5daabe4b8aedf8605e62017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-014j-0900000000-4ccd8055b59ae6eabc902017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-014i-1900000000-deb31ec7e47ca6a0e3ff2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-014i-1900000000-add8b8849c3db116e1812017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-014i-2900000000-c38a45f14fb4ab5b16872017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-014r-3900000000-1f2c04e07e8c46a0c7222017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0910000000-549410c48d9c44650beb2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0900000000-669fdf1a00514df13bf22017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0900000000-59e6f9e272a364ed620a2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-0002-0900000000-a9b1b534a7a36bdaf0142017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine LC-ESI-QFT , positive-QTOFsplash10-014i-0900000000-0d3c0ba161b03c4cc7d52017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine 60V, Positive-QTOFsplash10-0002-0900000000-b8fac5c4ad178dbca8f12021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine 75V, Positive-QTOFsplash10-014j-0900000000-8c102cbdd49b481d06272021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine 30V, Positive-QTOFsplash10-0002-0900000000-7af6ac1b513c7f2f33a92021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine 45V, Positive-QTOFsplash10-0002-0900000000-af33f4c17bcc16d14b332021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Pheniramine 15V, Positive-QTOFsplash10-0002-0920000000-fd728bb396d025cac3f02021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Pheniramine 10V, Positive-QTOFsplash10-0006-0190000000-7366bfe1512ab11f5f472016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Pheniramine 20V, Positive-QTOFsplash10-0007-0980000000-33028cde378f5ae398e22016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Pheniramine 40V, Positive-QTOFsplash10-01ba-3910000000-38e90d8ee368fe03cf5d2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Pheniramine 10V, Negative-QTOFsplash10-000i-0090000000-3a929a14b25a39d76c952016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Pheniramine 20V, Negative-QTOFsplash10-000i-1090000000-f70051070830e70028172016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Pheniramine 40V, Negative-QTOFsplash10-004i-8920000000-20990e9f1eda4700b6ce2016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01620 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01620 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB01620
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID4597
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkPheniramine
METLIN IDNot Available
PubChem Compound4761
PDB IDNot Available
ChEBI ID308661
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDrw1584301
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General ReferencesNot Available

Enzymes

General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular weight:
55783.6
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Leurs R, Bast A, Timmerman H: High affinity, saturable [3H]mepyramine binding sites on rat liver plasma membrane do not represent histamine H1-receptors. A warning. Biochem Pharmacol. 1989 Jul 1;38(13):2175-80. [PubMed:2567596 ]
  3. Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410 ]
  4. Nath C, Gupta MB: Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82. [PubMed:11526976 ]
  5. Karadag CH, Ulugol A, Dokmeci D, Dokmeci I: The role of histamine H1-receptors in the anticonvulsive effect of morphine against maximal electroconvulsive shock in mice. Jpn J Pharmacol. 1996 Jun;71(2):109-12. [PubMed:8835636 ]
  6. Nosal R, Drabikova K, Jancinova V, Moravcova J, Lojek A, Ciz M, Macickova T, Pecivova J: H1-antihistamines and oxidative burst of professional phagocytes. Neuro Endocrinol Lett. 2009;30 Suppl 1:133-6. [PubMed:20027159 ]
  7. Gepdiremen A, Buyukokuroglu ME, Hacimuftuoglu A, Suleyman H: Contribution of the histaminergic receptor subtypes to histamine-induced cerebellar granular neurotoxicity. Pol J Pharmacol. 2003 May-Jun;55(3):383-8. [PubMed:14506317 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]